Get started
Work

Quality of Life (QoL) and care pathway in patients with durable response to Immune Checkpoint Inhibitors (ICI-DR) for advanced or metastatic melanoma: QUALICI study

Year: 2025
Type: article
Abstract: Background: Immune checkpoint inhibitors (ICIs) have significantly improved the prognosis of advanced or metastatic melanoma in recent years, with patients experiencing durable responses to treatment. These patients face specific QoL challenges. The QUALICI study aimed to assess patients’ QoL, their experiences, and expectations about QoL management.
DOI: 10.1016/j.ejcskn.2025.100538
Authors: C. Robert, J. Bonastre, G. Spurrier, H. Lemasson, M. Chartier, V. Moreau-Mallet, S. Micheliza, N. Texier, S. Hervy, M. Coint Bavarot, N. Girard
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409145146
FWCI:
Cites:
Cited by:
Related to: 10